Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Neutral

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:30 ONCO · 0.81 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Most recent release (June 25, 2026): Editorial placement in BioMedWire highlighting the commercial growth of next-generation DNA Damage Response (DDR) inhibitors, noting a $7B+ market in 2025 and a ~$750B projected market by 2030. Positions ONC010 within this therapeutic shift. No new clinical, financial, or operational data is disclosed.
  • June 23, 2026: Services agreement with Nanosoft Polymers to advance polymer process development, analytical characterization, scale-up, and formulation optimization for ONC010. Aims to de-risk IND-enabling activities and GMP readiness.
  • June 19, 2026: Closed a $5M non-brokered private placement at $0.7392/unit. Also announced completion of a 300-gram API scale-up batch (99.3% purity) and appointment of Dave Antony as CFO.
  • Historical progression (March–June 2026): Continuous CMC scale-up (B4 precursor, A83, API), AI/computational collaborations (Kuano, AstraZeneca, GSK, OneMedNet), and repeated equity raises to fund operations. Management consistently guides toward IND filing and first-in-human trials in 2026/2027.
Material Impact
  • The June 25 editorial is a marketing/IR placement. It provides industry context but does not alter the company's clinical trajectory, financial position, or regulatory pathway.
  • The June 19 financing provides ~$5M in gross proceeds, extending operational runway, but at a significant discount to prior placements ($1.40 in Oct 2025, $0.88 in Jan 2026). This reflects downward valuation pressure and continued dilution.
  • The 300g API milestone and Nanosoft partnership are routine CMC and formulation steps for a preclinical candidate. They confirm manufacturing progress but do not de-risk clinical efficacy, safety, or regulatory approval.
  • Overall, the news is incremental and expected for a cash-burning preclinical biotech. It does not contain genuinely new, market-moving information that would re-rate the business.
ONCO · Price
Company Overview
  • Preclinical-stage biotechnology company developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways in solid tumors.
  • Wholly-owned subsidiary Inka Health Corp. advances SynoGraph, an AI-driven precision oncology platform leveraging multimodal data for clinical outcome prediction.
  • Partnerships include Dalton Pharma Services (CMC/scale-up), Nucro-Technics (preclinical/bioanalysis), Avance Clinical (clinical planning), and AI/data collaborations with AstraZeneca, GSK, OneMedNet, and Kuano.
  • Strategic goal: File IND, initiate Phase 1 first-in-human trials, and pursue a U.S. exchange cross-listing.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property Jun 19, 2026 · 19:00

Onco-Innovations Announces Non-Brokered LIFE Offering

Financings